Marshall Wace
CORT icon

Marshall Wace’s Corcept Therapeutics CORT Stock Holding History

Marshall Wace’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Sell
5,628
-13,064
-70% -$789K ﹤0.01% 2535
2026
Q1 		$753K Buy
+18,692
New +$699K ﹤0.01% 2272
2025
Q3 		– Sell
-46,200
Closed -$3.39M – 2960
2025
Q2 		$3.39M Buy
46,200
+41,040
+795% +$2.98M ﹤0.01% 1320
2025
Q1 		$589K Buy
+5,160
New +$314K ﹤0.01% 2016
2024
Q3 		– Sell
-20,200
Closed -$656K – 2567
2024
Q2 		$656K Sell
20,200
-78,299
-79% -$2.14M ﹤0.01% 1862
2024
Q1 		$2.48M Buy
+98,499
New +$2.33M ﹤0.01% 1257
2023
Q4 		– Sell
-19,042
Closed -$519K – 2229
2023
Q3 		$519K Sell
19,042
-168,584
-90% -$4.88M ﹤0.01% 1711
2023
Q2 		$4.17M Buy
187,626
+65,500
+54% +$1.51M 0.01% 1103
2023
Q1 		$2.65M Buy
+122,126
New +$2.68M 0.01% 1298
2022
Q4 		– Sell
-29,372
Closed -$753K – 2993
2022
Q3 		$753K Sell
29,372
-25,596
-47% -$685K ﹤0.01% 2546
2022
Q2 		$1.31M Buy
+54,968
New +$1.2M ﹤0.01% 2285
2021
Q3 		– Sell
-9,941
Closed -$219K – 3071
2021
Q2 		$219K Sell
9,941
-36,337
-79% -$809K ﹤0.01% 2420
2021
Q1 		$1.1M Sell
46,278
-205,122
-82% -$5.48M 0.01% 1611
2020
Q4 		$6.58M Sell
251,400
-298,682
-54% -$6.29M 0.04% 481
2020
Q3 		$9.58M Buy
+550,082
New +$8.77M 0.06% 313
2020
Q2 		– Sell
-538,555
Closed -$6.4M – 1603
2020
Q1 		$6.4M Buy
538,555
+484,178
+890% +$5.99M 0.06% 309
2019
Q4 		$658K Sell
54,377
-235,809
-81% -$3.28M ﹤0.01% 1084
2019
Q3 		$4.1M Sell
290,186
-13,318
-4% -$164K 0.03% 558
2019
Q2 		$3.38M Buy
303,504
+50,523
+20% +$563K 0.03% 610
2019
Q1 		$2.97M Sell
252,981
-320,855
-56% -$3.99M 0.03% 633
2018
Q4 		$7.67M Buy
573,836
+456,584
+389% +$6.03M 0.08% 318
2018
Q3 		$1.64M Buy
+117,252
New +$1.64M 0.01% 717

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's CORT Position: Q2 2026 in Review

Marshall Wace reduced its Corcept Therapeutics (CORT) stake by 70% in Q2 2026, selling an estimated $789K and leaving 5,628 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Marshall Wace first reported a position in CORT in Q3 2018 and has held it in 22 quarters since. The position peaked at $9.58M in Q3 2020. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Marshall Wace held 5,628 shares of Corcept Therapeutics worth $489K as of Q2 2026.
  • Marshall Wace sold 13,064 Corcept Therapeutics shares in Q2 2026, an estimated $789K.
  • Corcept Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2535 holding.
  • Marshall Wace first reported a position in Corcept Therapeutics in Q3 2018 and has held it in 22 quarters since.
  • Marshall Wace's Corcept Therapeutics position peaked at $9.58M in Q3 2020.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.